Loading...
Loading...
Seattle
Genetics
SGEN today announced the initiation of a
phase 1 clinical trial evaluating SGN-LIV1A for patients with
LIV-1-positive metastatic breast cancer. SGN-LIV1A utilizes Seattle
Genetics' industry-leading antibody-drug conjugate (ADC) technology. The
trial is designed to assess the safety and antitumor activity of
SGN-LIV1A, an ADC targeted to LIV-1 (SLC39A6), a protein which is
expressed in most subtypes of metastatic breast cancer.
“ADCs represent a novel treatment approach that have demonstrated
activity in both hematologic and solid tumors. SGN-LIV1A is one of four
ADCs that we are advancing into the clinic during 2013, demonstrating
our significant investment in this approach for the treatment of
cancer,” said Jonathan
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ex-Date | ticker | name | Dividend | Yield | Announced | Record | Payable |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in